Ascendis Pharma A/S (ASND)
127.64
-0.20
(-0.16%)
USD |
NASDAQ |
Jun 14, 16:00
128.09
+0.45
(+0.35%)
After-Hours: 20:00
Ascendis Pharma Gross Profit (TTM): 305.11M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 305.11M |
| December 31, 2023 | 240.29M |
| September 30, 2023 | 131.13M |
| June 30, 2023 | 100.58M |
| March 31, 2023 | 68.40M |
| Date | Value |
|---|---|
| December 31, 2022 | 40.18M |
| September 30, 2022 | 23.57M |
| June 30, 2022 | 11.19M |
| March 31, 2022 | 7.013M |
| December 31, 2021 | 5.014M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
5.014M
Minimum
Dec 2021
305.11M
Maximum
Mar 2024
93.25M
Average
54.29M
Median
Gross Profit (TTM) Benchmarks
| Evaxion Biotech AS | -- |
| Biodexa Pharmaceuticals Plc | -4.597M |
| Trinity Biotech PLC | 19.40M |
| Cellectis SA | -- |
| NuCana PLC | -- |